[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

CurrentPartnering: Market Research Reports

Established in 2007, CurrentPartnering is a company, publishing deal terms and business development best practice reports, which offer access to business intelligence data and description of the recent and emerging trends in the partnering activity across a broad range of the life sciences industries. CurrentPartnering helps their clients to get ready for negotiations and gain better understanding of the potential deal structures available to them.

The list of CurrentPartnering’s customers is represented by numerous bigpharma, diagnostics, pharmaceutical and biotech companies. The reports published by CurrentPrartnering deliver to their clients assessment of potential partnerships terms, in-depth insights into the major financial terms and other key issues essential for successful partnering. CurrentPartnering supplies its customers with cutting-edge information required to optimize their partnering activities.

Publications found: 71
Sort by:
Global Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2021 US$ 3,495.00

... the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies REPORT SCOPE Global Asset Purchase Deals in Pharma, Biotech and ...

October 2021 700 pages
Global Cardiovascular Partnering 2014-2021: Deal trends, players and financials US$ 3,495.00

... heart failure, Coronary artery disease, Ductus arteriosus, Fatigue, Hypercholesterolemia, Hypertension, Intermittent claudication, Ischemic heart disease, Limb ischemia, Marfan's Syndrome, Myocardial Infarction, Oedema (excess fluid), Palpitations, Peripheral arterial disease, Thrombus (blood clot), Valvular ...

October 2021 550 pages
Global Central Nervous System Partnering 2014-2021: Deal trends, players and financials US$ 3,495.00

... Cerebral palsy, Creutzfeldt Jakob disease, Dizziness, Epilepsy, Faints, Falls, Guillain Barre syndrome, Headache, Meningitis (Bacterial, Meningococcal, Pneumococcal), Mycobacterium tuberculosis (TB), Haemophilus influenzae Type B (Hib), Migraine, Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig ...

October 2021 1000 pages
Global Dental Partnering 2010-2021: Deal trends, players and financials US$ 3,495.00

... DESCRIPTION Global Dental Partnering 2014 to 2019 provides the full collection of Dental disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Dental partnering deals Financial deal terms ...

October 2021 200 pages
Global Gastrointestinal Partnering 2014-2021: Deal trends, players and financials US$ 3,495.00

... , Esophagitis, Gastritis, Gastroenteritis, Hemorrhoids (haemorrhoids), Hernia, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Irritable bowel syndrome, Malabsorption, Malnutrition, Pancreatitis, Peptic ulce, Gastric ulcer, Duodenal ulcer, Abdominal pain, Ascites, Bowel movement, Constipation ...

October 2021 350 pages
Global Dermatology Partnering 2014-2021: Deal trends, players and financials US$ 3,495.00

... deals for the following indications: Acne, Actinic keratosis, Angioedema, Burns, Cellulitis, Cosmetics, Dermatitis, Diabetic foot ulcer, Eczema, Hair disorders, Alopecia, Impetigo, Itching, Nail disorders, Psoriasis, Rosacea, Scabies, Sun damage, Rash, Scar, Venous ulcer, Verruca, Wound healing, Wrinkles ...

October 2021 400 pages
Global Genetic Disorders Partnering 2014-2021: Deal trends, players and financials US$ 3,495.00

... access to Genetic Disorders trends and structure of deals entered into by leading companies worldwide. Global Genetic Disorders Partnering 2014 to 2019 includes: Trends in Genetic Disorders dealmaking in the biopharma industry since 2014 Analysis of Genetic Disorders deal structure ...

October 2021 400 pages
Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 US$ 3,495.00

... manufacturing and supply deals by value since 2014 Most active manufacturing and supply dealmakers since 2014 The leading manufacturing and supply partnering resources In Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech ...

October 2021 1300 pages
Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2021 US$ 3,495.00

... Current Agreements deals and alliances database, providing easy access to each deal record on demand. The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 ...

October 2021 350 pages
Global Diagnostic Imaging Partnering Terms and Agreements 2014 to 2021 US$ 3,495.00

... imaging partnering deals. This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering: Imaging CT Endoscope Molecular and nuclear PET SPECT MRI Ultrasound X ray Angiography Fluoroscopy Mammography This report provides an overview of diagnostic imaging ...

October 2021 550 pages
Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2021 US$ 3,495.00

... including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche ...

October 2021 550 pages
Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2016-2021 US$ 3,495.00

... including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche ...

October 2021 2500 pages
Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2021 US$ 3,495.00

... DESCRIPTION The Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019 report provides details of the latest distribution agreements announced in the pharmaceutical, biotechnology and ...

October 2021 1300 pages
Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 US$ 3,495.00

... Joint venture alliances. KEY BENEFITS Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019 provides the reader with the following key benefits: In-depth understanding of joint venture partnering deal ...

October 2021 350 pages
Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2015-2021 US$ 3,495.00

... latest licensing agreements announced in the pharmaceutical, biotechnology ... licensing deals by value since 2014 Most active licensing dealmakers since 2014 The leading licensing partnering resources In Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014- 2019 available deals ...

October 2021 2600 pages
Global Option and Evaluation Partnership Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 US$ 3,495.00

... including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche ...

October 2021 1000 pages
Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2021 US$ 3,495.00

... including the technology licensed, royalty rates, license fees, upfront and milestone payments. DESCRIPTION The Global Royalty Rate Trends in Pharma ... licensed, royalty rates, license fees, upfront and milestone payments. This report provides details of the latest partnering deals which disclose a royalty rate ...

October 2021 500 pages
Global Autoimmune Partnering 2014-2021: Deal trends, players and financials US$ 3,495.00

... autoimmune diseases: Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn’s disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma ...

October 2021 700 pages
Global Coronavirus Partnering 2014-2021 US$ 3,495.00

SUMMARY The Global Coronavirus Partnering 2014-2021 report provides comprehensive understanding and unprecedented access to the coronavirus partnering agreements entered into by the worlds leading he...

October 2021 650 pages
Global Psychiatry Partnering 2014-2021: Deal trends, players and financials US$ 3,495.00

... DESCRIPTION Global Psychiatry Partnering 2014 to 2019 provides the full collection of Psychiatry disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Psychiatry partnering deals Financial deal terms ...

September 2021 550 pages
Global Infectious Diseases Partnering 2014-2021: Deal trends, players and financials US$ 3,495.00

... access to the infectives partnering deals and agreements entered into by the worlds leading healthcare companies DESCRIPTION Global Infectious Diseases Partnering 2014 to 2019 provides the full collection of Infectious Diseases disease deals signed between ...

September 2021 1500 pages
Global Metabolic Partnering 2014-2020: Deal trends, players and financials US$ 3,495.00

... DESCRIPTION Global Metabolic Partnering 2014 to 2019 provides the full collection of Metabolic disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Metabolic partnering deals Financial deal terms ...

September 2021 700 pages
Global Pediatrics Partnering 2010-2021: Deal trends, players and financials US$ 3,495.00

... to hundreds of Pediatrics deal contract documents Comprehensive access to over 200 Pediatrics deal records The leading Pediatrics deals by value since 2014 Most active Pediatrics dealmakers since 2014 In Global Pediatrics Partnering 2014 to 2019, available deals and ...

September 2021 500 pages
Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021 US$ 3,495.00

... 1,700 clinical stage deals The leading clinical stage deals by value since 2014 Most active clinical stage dealmakers since 2014 The leading clinical stage partnering resources In Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014 ...

September 2021 1900 pages
Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2021 US$ 3,495.00

... 2,000 discovery stage deals The leading discovery stage deals by value since 2014 Most active discovery stage dealmakers since 2014 The leading discovery stage partnering 2014 In Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014 ...

September 2021 2500 pages
Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021 US$ 3,495.00

... 1,200 preclinical stage deals The leading preclinical stage deals by value since 2014 Most active preclinical stage dealmakers since 2014 The leading preclinical stage partnering resources In Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014 ...

September 2021 1500 pages
Global Academic and Non-Profit Partnering Terms and Agreements 2015-2021 US$ 3,495.00

... Academic and Non-Profit deals Access to Academic and Non-Profit contract documents Leading Academic and Non-Profit deals by value since 2014 Most active Academic and Non-Profit dealmakers since 2014 In Global Academic and Non-Profit Partnering ...

September 2021 3000 pages
Global Animal Health Partnering Terms and Agreements 2010 to 2021 US$ 3,495.00

... access to actual Animal Health contracts entered into by leading biopharma companies Identify most active Animal Health dealmakers since 2014 Insight into terms included in a Animal Health partnering agreement, with real ...

September 2021 350 pages
Global Big Pharma Partnering Terms and Agreements 2014-2021 US$ 3,495.00

... an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson ...

September 2021 2400 pages
Global Biotech Partnering Terms and Agreements 2017-2021 US$ 3,495.00

SUMMARY Global Biotech Partnering Terms and Agreements 2014 to 2019 report provides a detailed understanding and analysis of how and why companies enter Biotech partnering deals DESCRIPTION Global Biotech Partnering Terms and Agreements 2014 ...

September 2021 3000 pages
Global Medical Device Partnering Terms and Agreements 2014-2021 US$ 3,495.00

SUMMARY Global Medical Device Partnering Terms and Agreements 2014-2019 report provides a detailed understanding and analysis of how and why companies enter Medical Device partnering deals DESCRIPTION Global Medical Device Partnering Terms and Agreements 2014 ...

September 2021 1500 pages
Global Pharmaceutical Partnering Terms and Agreements 2017-2021 US$ 3,495.00

SUMMARY Global Pharmaceutical Partnering Terms and Agreements 2014 to 2019 report provides a detailed understanding and analysis of how and why companies enter Pharmaceutical partnering deals DESCRIPTION Global Pharmaceutical Partnering Terms and Agreements 2014 ...

September 2021 3500 pages
Global Specialty Pharmaceutical Partnering Terms and Agreements 2014-2021 US$ 3,495.00

SUMMARY Global Specialty Pharmaceutical Partnering Terms and Agreements 2014 to 2019 report provides a detailed understanding and analysis of how and why companies enter Specialty Pharmaceutical partnering deals DESCRIPTION Global Specialty Pharmaceutical Partnering Terms and Agreements 2014 ...

September 2021 750 pages
Global Bioinformatics Partnering Terms and Agreements 2014 to 2021 US$ 3,495.00

... companies. Trends in bioinformatics partnering deals Deal terms analysis Partnering agreement structure Partnering contract documents Top deals by value Most active deal makers Financial deal terms for bioinformatics The Global Bioinformatics Partnering Terms and Agreements 2014 ...

June 2021 750 pages
Global Hematology Partnering 2010-2021: Deal trends, players and financials US$ 3,495.00

... DESCRIPTION Global Hematology Partnering 2014 to 2019 provides the full collection of Hematology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Hematology partnering deals Financial deal terms ...

June 2021 400 pages
Global Genitourinary Partnering 2010-2021: Deal trends, players and financials US$ 3,495.00

... DESCRIPTION Global Genitourinary Partnering 2014 to 2019 provides the full collection of Genitourinary disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Genitourinary partnering deals Financial deal terms ...

June 2021 400 pages
Global Gynecology Partnering 2010-2021: Deal trends, players and financials US$ 3,495.00

... scope Global Gynecology Partnering 2014 to 2019 is intended to provide the reader with an in-depth understanding and access to Gynecology trends and structure of deals entered into by leading companies worldwide. Global Gynecology Partnering 2014 to 2019 ...

June 2021 300 pages
Global Immunology Partnering 2014-2021: Deal trends, players and financials US$ 3,495.00

... DESCRIPTION Global Immunology Partnering 2014 to 2019 provides the full collection of Immunology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Immunology partnering deals Financial deal terms ...

June 2021 650 pages
Global Musculoskeletal Partnering 2014-2021: Deal trends, players and financials US$ 3,495.00

... DESCRIPTION Global Musculoskeletal Partnering 2014 to 2019 provides the full collection of Musculoskeletal disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Musculoskeletal partnering deals Financial deal terms ...

June 2021 400 pages
Global Oncology Partnering 2015-2021: Deal trends, players and financials US$ 3,495.00

... , Vomiting, Chemotherapy, Radiotherapy, Adenocarcinoma, Basal cell carcinoma, Bile duct cancer, Bladder cancer, Bone cancer, Brain cancer, Breast cancer, Cervical cancer, Colorectal cancer, Endometrial, Esophageal cancer, Gastric cancer, Head and neck cancer, Kaposi's sarcoma, Kidney cancer, Leukemia, Acute ...

June 2021 3000 pages
Global Hospital Care Partnering 2014-2021: Deal trends, players and financials US$ 3,495.00

... access to Hospital Care trends and structure of deals entered into by leading companies worldwide. Global Hospital Care Partnering 2014 to 2019 includes: Trends in Hospital Care dealmaking in the biopharma industry since 2014 Analysis of Hospital Care deal structure ...

June 2021 700 pages
Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2021 US$ 3,495.00

... access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies. DESCRIPTION The Global Regenerative Medicine Partnering 2014-2019: Deal trends, players ...

June 2021 900 pages
Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2021 US$ 3,495.00

... Access to over 640 monoclonal antibodies deal records The leading monoclonal antibodies deals by value since 2014 Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2014 In Global Monoclonal antibody Partnering Terms and Agreements 2014 to 2098 ...

June 2021 650 pages
Global Gene Therapy Partnering Terms and Agreements 2010 to 2021 US$ 3,495.00

... -life gene therapy deals Access to over 220 gene therapy deals The leading gene therapy deals by value since 2014 Most active gene therapy dealmakers since 2014 The leading gene therapy partnering resources In Global Gene Therapy Partnering Terms and ...

June 2021 400 pages
Global Molecular Diagnostics Partnering Terms and Agreements 2014 to 2021 US$ 3,495.00

... due diligence to assess suitability of your proposed deal terms for partner companies Report scope Global Molecular Diagnostics Partnering 2014-2019: Deal trends, players, financials and forecasts is intended ...

June 2021 550 pages
Global Genomics Partnering Terms and Agreements 2014 to 2021 US$ 3,495.00

... , upfronts, milestones and royalties by stage of development Genomics partnering contract documents Top Genomics deals by value The Global Genomics Partnering Terms and Agreements report provides an understanding and ...

June 2021 600 pages
Global Microbiome Partnering Terms and Agreements 2010 to 2021 US$ 3,495.00

... , upfronts, milestones and royalties by stage of development Microbiome partnering contract documents Top Microbiome deals by value The Global Microbiome Partnering Terms and Agreements report provides an understanding and ...

June 2021 150 pages
Global Proteomics Partnering Terms and Agreements 2010 to 2021 US$ 3,495.00

... , upfronts, milestones and royalties by stage of development Proteomics partnering contract documents Top Proteomics deals by value The Global Proteomics Partnering Terms and Agreements report provides an understanding and ...

June 2021 400 pages
Global Biosimilars Partnering Terms and Agreements 2010 to 2021 US$ 3,495.00

... fifty big pharma companies Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies

June 2021 150 pages
Global Companion Diagnostics Partnering Terms and Agreements 2010-2021 US$ 3,495.00

... Case studies of real-life Companion Diagnostics deals Access to Companion Diagnostics contract documents Leading Companion Diagnostics deals by value since 2014 Most active Companion Diagnostics dealmakers since 2014 In Global Companion Diagnostics Partnering 2014-2019: Deal trends, players, financials and ...

May 2021 300 pages

Filters

Search

Categories

20
2
1
1
1
7
1
25
1
4
2
1
1
1
1
1
1

Publishers

71

Regions

71

Price

Date

Pages

Offers